Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERGain chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer
2023-509923-42-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of trastuzumab and pertuzumab in breast cancer (3 cohorts), sponsored by MEDSIR. Primary endpoints: Pathologic complete response in PET responders and 3-year invasive disease-free survival. Planned start Jul 2017; status: authorised.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-509923-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509923-42-00.